Compare EBMT & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EBMT | STTK |
|---|---|---|
| Founded | 1922 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 170.5M | 275.9M |
| IPO Year | 2009 | 2020 |
| Metric | EBMT | STTK |
|---|---|---|
| Price | $20.99 | $5.99 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $23.00 | $7.00 |
| AVG Volume (30 Days) | 30.0K | ★ 569.8K |
| Earning Date | 04-28-2026 | 06-11-2026 |
| Dividend Yield | ★ 2.71% | N/A |
| EPS Growth | ★ 53.23 | 53.02 |
| EPS | ★ 1.90 | N/A |
| Revenue | N/A | ★ $1,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.00 | N/A |
| P/E Ratio | $11.06 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $15.11 | $0.69 |
| 52 Week High | $23.75 | $6.13 |
| Indicator | EBMT | STTK |
|---|---|---|
| Relative Strength Index (RSI) | 39.31 | 75.86 |
| Support Level | $15.93 | $1.85 |
| Resistance Level | $23.04 | N/A |
| Average True Range (ATR) | 0.71 | 0.39 |
| MACD | -0.20 | 0.19 |
| Stochastic Oscillator | 16.08 | 96.33 |
Eagle Bancorp Montana Inc operates as a bank holding company. It provides loan and deposit services. The company focuses on residential loans, commercial real estate loans, commercial loans, consumer loans, and home equity loan products. The bank also offers deposit accounts which include checking, savings, money market, individual retirement accounts, and certificates of deposit accounts. It is a diversified lender with a focus on residential mortgage loans, commercial real estate mortgage loans, commercial business loans, agricultural loans, and second mortgage/home equity loan products.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.